Tools
Stock profile

SUPERNUS PHARMACEUTICALS, INC. (SUPN)

SUPN · Latest close $28.96 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$28.96
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

SUPERNUS PHARMACEUTICALS, INC. (SUPN) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Latest close $28.96 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Third Avenue Management · Axiom Investors — 2 tracked funds hold SUPN. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Third Avenue Management1.14%152,724HELD Q3 filed Nov 13
Axiom Investors0.04%94,465TRIMMED (-42.4%) Q3 filed Nov 12

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -27.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

41.836.912024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding333 of 8,857 filers
Long-only filers among them331
Change vs 2026 Q1+14 net · 321 entered · 307 exited
Shares reported, all filers60,230,061
Reported value, all filers$2.7B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$719.0M
Net income · FY2025$-38.5M
Total assets · FY2025$1.5B
Shares outstanding58,235,716
Market cap (at latest close)$1.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 27, 2026.

Short interest

Shares short · Oct 15, 20264,043,677
Share of shares outstanding6.94%
Days to cover4.93

Shares short at recent settlements — Jul 31, 2026: 4.8M · Aug 14, 2026: 4.1M · Aug 31, 2026: 4.7M · Sep 15, 2026: 5.0M · Sep 30, 2026: 5.0M · Oct 15, 2026: 4.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 27, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 27, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Mar 17, 2026PADMANABH P BHATTOfficer57,250$2.9MMar 17, 2026SEC filing
Mar 16, 2026PADMANABH P BHATTOfficer50,000$2.5MMar 16, 2026SEC filing
Mar 13, 2026THE KBT TRUST U/A DTD 12/30/2010Director, Officer35,000$1.8MMar 13, 2026SEC filing
Mar 12, 2026FREDERICK M HUDSONDirector5,369$271.8KMar 12, 2026SEC filing
Mar 10, 2026WILLIAM TODD HORICHOfficer4,439$244.1KMar 10, 2026SEC filing
Mar 9, 2026WILLIAM TODD HORICHOfficer4,438$239.7KMar 9, 2026SEC filing
Mar 9, 2026FRANK MOTTOLAOfficer1,623$87.1KMar 9, 2026SEC filing
Mar 6, 2026GEORGES GEMAYELDirector8,787$465.8KMar 6, 2026SEC filing
Mar 5, 2026GEORGES GEMAYELDirector10,000$537.1KMar 5, 2026SEC filing
Feb 19, 2026BETHANY SENSENIGDirector4,475$224.6KFeb 19, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 6, 2026Integrated Core Strategies (US) LLCSC 13G/A3,605,2276.2%Jun 30, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G2,900,8845.0%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G3,263,3095.7%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 18, 2026Integrated Core Strategies (US) LLCSC 13G/A2,817,8834.9%Feb 11, 2026SEC filing
Feb 17, 2026Armistice Capital, LLCSC 13G/A2,764,0004.8%Dec 31, 2025SEC filing
Feb 2, 2026Millennium Management LLCSC 13G3,036,1235.3%Jan 26, 2026SEC filing
Jan 21, 2026Dimensional Fund Advisors LPSC 13G/A2,712,3414.7%Dec 31, 2025SEC filing
Nov 14, 2025Armistice Capital, LLCSC 13G/A2,836,0005.1%Sep 30, 2025SEC filing
Aug 15, 2025Armistice Capital, LLCSC 13G/A4,812,0008.6%Jun 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 54 Lobbying Disclosure Act filings named this company as client, 2018–2026; most common issues: Health Issues (54), Medicare/Medicaid (24).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

This stock does not currently pass any tracked screen.

Also held by the tracked funds that hold SUPN — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 2, 20263.01 Notice of Delisting or Failure to Satisfy a Continued Listing RuleSEC filing
Nov 2, 20261.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 2.03 Creation of a Direct Financial Obligation · 3.03 Material Modification to Rights of Security Holders · 5.01 Changes in Control of Registrant · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on SUPN

One email a week: the week’s new filings and research. Subscribe free

← SUNC  ·  SVA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.